Drugs / KT501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07234773 | Mar 2026 → Feb 2027 expected | rheumatoid arthritis | Kali Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-03 | Kali Therapeutics, Inc. | Regulatory Kali Therapeutics Receives U.S. FDA Clearance for KT501 InvestigationalNew Drug Application kalitherapeutics.com ↗
Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for KT501. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-03 | Kali Therapeutics, Inc. | Kali Therapeutics Receives U.S. FDA Clearance for KT501 InvestigationalNew Drug Application kalitherapeutics.com ↗ |
| 2026-03-18 | Kali Therapeutics, Inc. | Kali Therapeutics Announces First Patient Dosed in Phase1a Clinical Trial of KT501 for Rheumatoid Arthritis kalitherapeutics.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KT501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07234773 ↗ |
| Action | Deplete | “depletes B cells including plasma cells” NCT07234773 ↗ |
| Modality | Monoclonal antibody | “KT501 is a monoclonal antibody” NCT07234773 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07234773 ↗ |
| Target | CD19 | “targeting CD19, BCMA and CD3” NCT07234773 ↗ |